LLY Lilly (Eli) FILING REVIEW ONLY
FORM 10-K · FY2025 ENDED 2025-12-31 · FILED 2026-02-12 · 899M DILUTED WTD-AVG SHARES
?
Diluted weighted-average shares: the average share count across the fiscal year, including shares that in-the-money options and awards would add — the denominator of diluted EPS.
· EDGAR ↗

The company discovers, develops, manufactures, and markets human pharmaceutical products, operating in a single business segment. Its product lines are organized across therapeutic areas including cardiometabolic health, oncology, immunology, and neuroscience, with individual products addressing conditions such as diabetes, obesity, various cancers, autoimmune and inflammatory diseases, and Alzheimer's disease. Customers include wholesalers, pharmacy benefit managers, insurers, managed care organizations, hospitals, government and long-term care institutions, and retail pharmacies, with products also promoted directly to healthcare providers and, in certain markets, to consumers.

S&P 500 · HEALTH CARE · CIK 59478
REVENUE$65.2B+44.7% YoY
NET INCOME$20.6B+94.9% YoY
OPERATING CASH FLOW$16.8B+90.7% YoY
68
FILING SCORE / 100
?
How the score is computed: 8 management claims are checked against the filed statements and 6 earnings-quality warning signs are computed from them. Each check earns 2 points when the numbers fully back it, 1 when partly, 0 when they contradict or flag red — 11/16 on claims and 8/12 on warning signs, averaged to 0–100. 70+ reads strong; 45–69 mixed; below 45 weak. Every check's arithmetic is on this page.
MIXED14 CHECKS · 1 red · 2 watchNEXT 10-Q ~AUG 2026 (EST.)
?
Estimated from the filer's own quarter cadence: last filed quarter end + one quarter; filing typically ~40 days later. An estimate, not an announcement.
Statements & commentary
?
Statements as filed on the left — every figure from the company's own XBRL filing, in millions of dollars. What management wrote on the right, quoted verbatim. Open any claim for its arithmetic. The gold number beside a statement line counts the claims resting on that line. ✓ matches · ◐ partly · ✗ contradicts or red flag · ◐ watch.
EVERY FIGURE AS FILED · $M EXCEPT PER-SHARE
Income statement · $ millions202520242023
Total revenues65,17945,04334,1244
· Product60,95840,74828,814
· Collaborationand other revenue4,2214,2955,310
Cost of revenue11,0528,4187,0821
Selling, general and administrative11,0948,5947,4042
Depreciation, depletion and amortization1,9971,7671,527
Interest expense486
Other income (expense), net(571)(219)97
Income before income taxes25,73112,6806,5541
Income tax provision5,0912,0901,3142
— of which current6,7984,7733,6551
Net income attributable to common20,64010,5905,2402
Diluted earnings per share$22.95$11.71$5.801
Weighted-average diluted shares899904903
Cash flow · $ millions202520242023
Net income incl. noncontrolling interests20,64010,5905,240
Depreciation, depletion and amortization1,9971,7671,527
Share-based compensation626646629
Deferred income taxes(1,707)(2,683)(2,341)
Change in inventories4,6712,5071,425
Change in payables10,1872,6094,274
Net cash provided by operating activities16,8138,8184,2403
Net cash used in investing activities(10,972)(9,302)(7,153)
Dividends paid5,3844,6804,069
Repurchases of common stock4,1082,500750
Debt issued13,16711,4173,959
Debt repaid7786640
Net cash used in financing activities(2,213)1,2303,496
Cash and equivalents at end of period7,2683,2682,819
Balance sheet · $ millions20252024
Cash and cash equivalents7,2683,2681
Short-term investments155
Receivables, net17,76011,0061
Inventories13,7447,5891
Total current assets55,62932,740
Property, plant and equipment, net24,67517,102
Goodwill5,8985,7701
Intangible assets, net6,5216,166
Total assets112,47678,7151
Accounts payable5,3793,229
Current debt1,6355,1171
Total current liabilities35,22828,376
Long-term debt40,86828,5271
Stockholders' equity26,53514,272
Noncontrolling interests80
Total equity14,272
Largest FY/FY moves · $ millions, ranked by |Δ|FY2025FY2024Δ $Δ %Reading
Total assets · BS112,47678,715+33,761+42.9%
Total current assets · BS55,62932,740+22,889+69.9%◐ outsized
· Product · IS60,95840,748+20,210+49.6%
Total revenues · IS65,17945,043+20,136+44.7%
Income before income taxes · IS25,73112,680+13,051+102.9%◐ outsized
Long-term debt · BS40,86828,527+12,341+43.3%
Stockholders' equity · BS26,53514,272+12,263+85.9%◐ outsized
Net income attributable to common · IS20,64010,590+10,050+94.9%◐ outsized
Net income incl. noncontrolling interests · CF20,64010,590+10,050+94.9%◐ outsized
Net cash provided by operating activities · CF16,8138,818+7,995+90.7%◐ outsized
Change in payables · CF10,1872,609+7,578+290.5%◐ outsized
Property, plant and equipment, net · BS24,67517,102+7,573+44.3%
Total current liabilities · BS35,22828,376+6,852+24.1%
Receivables, net · BS17,76011,006+6,754+61.4%◐ outsized
Business quality — Buffett/Munger screen · deterministic · not part of the filing scoreValueReading
Return on equity
net income ÷ average of start- and end-of-year equity
101.2%
sector median 13.1%
strong
Share count, year-end
(year-end shares − prior year-end) ÷ prior year-end
-0.3%
sector median -0.3%
flat
Debt to equity
(current debt + long-term debt) ÷ year-end equity
1.60
sector median 0.65
leveraged
FCF consistency
operating cash flow − capital expenditure, per year
n/ainsufficient data
Margin stability
pre-tax income ÷ revenue, swing across up to five years
pre-tax margin 39.5%
sector median 14.5%
volatile
Quarterly · as filed in 10-Q/10-K · $ millionsSEP 24MAR 25JUN 25SEP 25MAR 26
Total revenues11,43912,72915,55817,60119,799
Cost of revenue2,1712,2252,4483,0083,577
Selling, general and administrative2,1002,4682,7532,7412,934
Depreciation, depletion and amortization463509
Interest expense193244249180
Other income (expense), net62(239)(91)(133)(65)
Income before income taxes1,5883,4566,7767,2328,850
Income tax provision6186971,1161,6501,454
Net income attributable to common9702,7595,6605,5827,396
Diluted earnings per share$1.07$3.06$6.29$6.21$8.26
Weighted-average diluted shares905901900899896
Net cash provided by operating activities1,6665,333
Largest QoQ moves · latest vs prior filed quarterPriorLatestΔ $Δ %
Net cash provided by operating activities1,6665,333+3,667+220.1%
Total revenues17,60119,799+2,198+12.5%
Net income attributable to common5,5827,396+1,814+32.5%
Income before income taxes7,2328,850+1,618+22.4%
Cost of revenue3,0083,577+569+18.9%
Income tax provision1,6501,454−196-11.9%
Selling, general and administrative2,7412,934+193+7.0%
Interest expense249180−69-27.7%
Ownership — insiders & floatForm 4 + 10-K cover · open-market trades onlyValueReading
Public float$807,887M10-K cover · as of 2025-06-30
Insider Form 4s, 90d15 filings · 0 buys / 3 sellsnet selling · −$18,631,462
· Lilly Endowment IncSELL $13,554,964Form 4 filed 2026-05-07 · open market
· Yuffa IlyaSELL $2,876,925Form 4 filed 2026-06-11 · open market
· Lilly Endowment IncSELL $2,199,572Form 4 filed 2026-05-07 · open market
Insider ownership %needs the proxy statement — not read yet, never estimated
Institutional %needs 13F aggregation — not read yet, never estimated
Five-year seriesEACH OPENS ITS OWN PAGE WITH DERIVATION AND HISTORY
Terms and acronyms used on this page
Income statement & cash flow
ImpairmentA write-down of an asset's carrying value. Non-cash, and it does not reverse. A large impairment in one year flatters the next year's comparison.
OCFOperating cash flow — net cash provided by operating activities, as reported.
FCFFree cash flow. Not a GAAP measure and not defined in this filing. Derived here as operating cash flow less additions to oil and gas property less leasehold acquisitions. The method is shown wherever the figure is used.
Balance sheet & market
Public floatThe market value of shares held by non-affiliates, disclosed on the 10-K cover at the prior 30 June. Converting it to a float percentage needs a share price on that date, which the filing does not contain.
Filing & document terms
10-KThe annual report filed with the SEC. Item 7 is management's discussion and analysis; Item 1A is risk factors; Item 8 and Item 15 carry the audited financial statements.
YoY · CAGRYear over year · compound annual growth rate.
Keep readingWHERE AN ANALYST GOES NEXT

Not investment advice. DHI Signal publishes impersonal, rules-based research; no recommendation to buy or sell any security is made or implied. Every statement figure is transcribed from Lilly (Eli)'s Form 10-K for FY2025 (accession 0000059478-26-000013), pulled from EDGAR XBRL. Derived measures are computed only from lines shown on this page and the arithmetic is displayed so it can be checked. LLY is not in the tracked book. Market posture attaches only when the dashboard feed carries the name; this page computes none of it.